Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

French Technology Transfer Office offers new potent blocker of HER2 receptor for treatment of metastatic breast cancer

Country of Origin: France
Reference Number: TOFR20171005001
Publication Date: 9 November 2017

Summary

A French Unviversity (Technology Transfer Office) offers a new potent blocker of HER2 receptor for :
- the treatment of breast cancer's brain metastases
- the treatment against HER2+ breast cancers resistance
- the potential treatment of other HER2+ cancers (ovarian, gastric, salivary, neuroblastoma etc). 
The TTO of this University is looking for companies to license in this technology or for research cooperation.

Description

The French TTO (Technology Transfer Office) is acting on behalf of an established public laboratory of an university of the Paris region.

Breast cancer is the top cancer in women worldwide and is increasing particularly in developing countries where the majority of cases are diagnosed in late stages.1.7 million new cases of breast cancer occurred among women worldwide in 2012 (most recent data available)

20 to 30% of breast cancers are related to an overexpression of HER2 and among them, 20 to 40% express p95HER2, a truncated version of the receptor believed to play a role in cancer resistance.

Despite the benefits of the recent therapies targeting HER2 (Herceptin®, Perjeta® and Tykerb®), a large part of patients relapses because of treatment failure due to cancer resistance or toxicity issues. Notably, 20% to 50% of HER2 metastatic breast cancer patients die of brain metastases.

It was recently found that targeting a new domain of HER2 prevents the activation of HER2 signalization and may constitute a novel therapeutic approach. The present offer proposes two compound families targeting this domain and inhibiting specifically HER2 downstream signaling pathways in breast cancer. The compounds are able to cross the blood-brain barrier and, therefore, to target brain metastases.

The TTO of this University is looking for companies or universities in order to license this technology or to collaborate in its development.

Advantages and Innovations

New intracellular target domain on HER2 protein 
Effective on HER2 wild type as well as known drug resistant mutants such as p95HER2
Small molecules crossing the Blood-Brain Barrier to target brain metastases

Stage Of Development

Available for demonstration

Stage Of Development Comment

In vitro proof of concept in SKBR3 and BT474 human tumor cell lines 
Ongoing: in vivo proof of concept with hit compound on human tumor xenografts in mouse

Requested partner

The partner sought could be an university or a company interested in a license agreement or a research cooperation agreement or a technical cooperation agreement

Cooperation offer ist closed for requests